Disease-specific Working Groups
Improving outcomes in diabetes and breast cancer
How do you define the value of a medicine? An acute cancer patient prizes quality of life, while a clinician emphasizes clinical efficacy. Agreement on what constitutes value would focus resources on new medicines that improve outcomes for patients and society.
European Healthcare Innovation Leadership Network members recognized that moving the value discussion from the abstract to the concrete requires a disease-specific focus.
To develop disease-specific value frameworks, Tapestry convened type 2 diabetes and breast cancer Working Groups consisting of leading medical experts, regulators, payers, reimbursement authorities, patients, and industry representatives. These disease areas were chosen for their high impact on patients and high costs.
In 2009, Working Group participants established a shared value framework for evaluating new medicines, thereby increasing transparency and collaboration among all stakeholders throughout the drug development process. This framework sought to provide guidance on what constitutes value in a new medicine and how to demonstrate that value across constituencies.
Recognizing the inherent limitations of a static framework, the Working Groups recommended creating a new cross-stakeholder approach for evaluating medicines early in the drug development process. This led to the multi-stakeholder pilot initiative launched in 2010, which allowed for greater specificity than the original frameworks while preserving the collaborative culture of the Working Groups.
Learn more about the type 2 diabetes Working Group
Learn more about the breast cancer Working Group
Learn more about the multi-stakeholder pilot initiative
Recent Working Group topics:
